What Are MSCs?
Originally Authored by Jon A. Rowley, PhD, Founder (February 15, 2014), Updated by Iain Farrance, PhD Technical Marketing Associate (January 9, 2020) What’s in a Name? MSC is the traditional ... More
MSCs & Characterization
Meeting the growing needs of the perinatal RegenMed Industry: the only Umbilical Cord hMSC (hUC-MSC) system designed for today’s translationally focused research and product development
Authored by Iain Farrance, PhD, Technical Marketing Associate Introduction Human mesenchymal stromal cells (hMSC) are considered the “workhorse” of Regenerative Medicine (RegenMed). hMSC are a critical starting material in a growing variety of ... More
Comparability of hMSC Economic and Quality Attributes after Expansion in Bovine Serum Containing vs Xeno-Free Bioprocessing Media Formulations
Human Mesenchymal Stem/Stromal Cells (hMSCs), from bone marrow or other tissues, are poised to have the most significant impact on Regenerative Medicine compared to any other single cell type. This ... More
Cryopreserved hMSCs maintain comparable in vitro functional activity compared to fresh hMSCs
INTRODUCTION: Human mesenchymal stem cells (hMSC) are currently in use in over 400 clinical trials and are critical components of tomorrow’s cell-based products and devices (1, 2, 3). The secretion ... More
Adipose- and Bone Marrow-Derived hMSCs: What’s the Difference?
INTRODUCTION: Human Mesenchymal Stem/Stromal Cells, or hMSC, are key components of future therapeutics, engineered tissues, and medical devices and are currently in use in over 400 clinical trials (1). ... More
Priming of hMSCs to Improve Potency
By Iain Farrance, Priya Baraniak, and Jon Rowley. RoosterBio. In this blog, we will present internal data and information on priming RoosterBio’s bone marrow-derived human MSCs (hMSC) with pro-inflammatory molecules ... More
Current Bottlenecks in MSC Research: MSC Misconceptions
We blogged recently about Mesenchymal Stem/Stromal Cell (MSC) Misconceptions that are holding the translational cell therapy field back, as identified by Donald Phinney and Luc Sensebé. Since we have come ... More
Current Bottlenecks in MSC Research: Widespread MSC Misconceptions
We blogged several months ago about bottlenecks in the bioprocessing of Mesenchymal Stem Cells that are impeding their clinical translation. While the development of robust and scalable manufacturing methods, reduced ... More
Best Practices in MSC R&D: Addressing Donor Variability within your Experimental System
Human MSCs are the single most used cell source for tissue engineering and regenerative medicine applications, and clinical trials involving hMSCs have outpaced all other cell types in recent years ... More
Best Practices in MSC Culture: Tracking and Reporting Cellular Age Using Population Doubling Level (PDL) and not Passage Number
There has been much discussion in the literature and the blogosphere (here, here, and here) lately about keeping track of cellular age, and there is a very good reason for ... More